Literature DB >> 34226975

The first internal electromagnetic motion monitoring implementation for stereotactic liver radiotherapy in China: procedures and preliminary results.

Zhongde Mu1, Qi Wang2, Chang Guo2, Yong Feng2, Hongcheng Gu3, Zhenyu Zhai2, Jianfeng Wu2, Xia He4.   

Abstract

BACKGROUND: Respiratory motion may compromise the dose delivery accuracy in liver stereotactic body radiation therapy (SBRT). Motion management can improve treatment delivery. However, external surrogate signal may be unstable and inaccurate. This study reports the first case of liver SBRT based on internal electromagnetic motion monitoring (Calypso, Varian Medical Systems, USA) in China.
MATERIALS AND METHODS: The patient with a primary liver cancer was treated with respiratory-gated SBRT guided by three implanted electromagnetic transponders. The treatment was carried out in breath-hold end-exhale with beam-on when the centroid of the three transponders drifted within 5 mm (left-right (LR), anterior-posterior (AP) and cranio-caudal (CC) directions) from the planned position. The motion monitoring treatments were delivered in breath-hold end-exhale mode with the energy of 6 MV in FFF mode with 1200 monitor units (MU) per minute. For each fraction, QA results, intertransponder distances, geometric checks as well as tumor motion logs were explicitly recorded.
RESULTS: Comparing with the plan data, distance variances between each two transponders were - 0.56 ± 0.32 mm, 0.17 ± 0.33 mm and - 0.82 ± 0.68 mm. Geometric residual, the pitch, roll and yaw angles were 0.48 ± 0.21 mm (threshold 2.0 mm), 2.17° ± 1.85° (threshold 10°), - 2.42° ± 1.51° (threshold 10°) and 1.67° ± 1.07° (threshold 10°), respectively. The delivery time of the five fields were 13.8 s, 13.1 s, 11.2 s, 11.6 s, and 11.6 s with the average value of 12.3 ± 1.1 s. Treatment duration of each fraction ranged from 6.2 to 21.4 min, with the average value of 11.3 ± 5.0 min.
CONCLUSIONS: The first case of liver SBRT patient of China based on internal electromagnetic motion monitoring was performed. The system had a high tracking accuracy, and it did not delay the treatment time. In addition, the patient did not show any severe side effects except for grade I myelotoxicity. The internal electromagnetic motion monitoring system provides a real-time and direct way to track liver tumor targets.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Beacon transponder; Internal electromagnetic motion monitoring; Motion management; Radiotherapy; Stereotactic liver radiotherapy

Mesh:

Year:  2021        PMID: 34226975     DOI: 10.1007/s00432-021-03726-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Comparative assessment of liver tumor motion using cine-magnetic resonance imaging versus 4-dimensional computed tomography.

Authors:  Annemarie T Fernandes; Smith Apisarnthanarax; Lingshu Yin; Wei Zou; Mark Rosen; John P Plastaras; Edgar Ben-Josef; James M Metz; Boon-Keng Teo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

2.  Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy.

Authors:  Patrick Kupelian; Twyla Willoughby; Arul Mahadevan; Toufik Djemil; Geoffrey Weinstein; Shirish Jani; Charles Enke; Timothy Solberg; Nicholas Flores; David Liu; David Beyer; Lisa Levine
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-12-21       Impact factor: 7.038

3.  Audio-visual biofeedback for respiratory-gated radiotherapy: impact of audio instruction and audio-visual biofeedback on respiratory-gated radiotherapy.

Authors:  Rohini George; Theodore D Chung; Sastry S Vedam; Viswanathan Ramakrishnan; Radhe Mohan; Elisabeth Weiss; Paul J Keall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-01       Impact factor: 7.038

4.  Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer.

Authors:  Gordon O Schoenfeld; Robert J Amdur; Christopher G Morris; Jonathan G Li; Russell W Hinerman; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

5.  Technical Note: Validation and implementation of a wireless transponder tracking system for gated stereotactic ablative radiotherapy of the liver.

Authors:  Joshua James; Ashley Cetnar; Neal E Dunlap; Corinna Huffaker; Vi Nhan Nguyen; Melissa Potts; Brian Wang
Journal:  Med Phys       Date:  2016-06       Impact factor: 4.071

6.  Automatic online and real-time tumour motion monitoring during stereotactic liver treatments on a conventional linac by combined optical and sparse monoscopic imaging with kilovoltage x-rays (COSMIK).

Authors:  Jenny Bertholet; Jakob Toftegaard; Rune Hansen; Esben S Worm; Hanlin Wan; Parag J Parikh; Britta Weber; Morten Høyer; Per R Poulsen
Journal:  Phys Med Biol       Date:  2018-03-08       Impact factor: 3.609

7.  Accuracy and consistency of respiratory gating in abdominal cancer patients.

Authors:  Jiajia Ge; Lakshmi Santanam; Deshan Yang; Parag J Parikh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-18       Impact factor: 7.038

8.  The use of the Active Breathing Coordinator throughout radical non-small-cell lung cancer (NSCLC) radiotherapy.

Authors:  Juliet Brock; Helen A McNair; Niki Panakis; Richard Symonds-Tayler; Phil M Evans; Michael Brada
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

9.  Three-dimensional motion of liver tumors using cine-magnetic resonance imaging.

Authors:  Anna Kirilova; Gina Lockwood; Perry Choi; Neelufer Bana; Masoom A Haider; Kristy K Brock; Cynthia Eccles; Laura A Dawson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-02-06       Impact factor: 7.038

Review 10.  Image guidance: past and future of radiotherapy.

Authors:  H Herrmann; Y Seppenwoolde; D Georg; J Widder
Journal:  Radiologe       Date:  2019-12       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.